Cargando…
Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China
BACKGROUND: Clinical guidelines generally recommend endocrine therapy (ET) as first-line treatment of hormone receptor-positive advanced breast cancer (HR+ ABC) whereas chemotherapy (CT) should be considered in the presence of life-threatening disease or limited clinical benefit after three sequenti...
Autores principales: | Wu, Yun, Han, Yiqun, Yu, Pei, Ouyang, Quchang, Yan, Min, Wang, Xiaojia, Hu, Xichun, Jiang, Zefei, Huang, Tao, Tong, Zhongsheng, Wang, Shusen, Yin, Yongmei, Li, Hui, Yang, Runxiang, Yang, Huawei, Teng, Yuee, Sun, Tao, Cai, Li, Li, Hongyuan, Chen, Xi, He, Jianjun, Liu, Xinlan, Yang, Shune, Qiao, Youlin, Fan, Jinhu, Wang, Jiayu, Xu, Binghe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905089/ https://www.ncbi.nlm.nih.gov/pubmed/33643905 http://dx.doi.org/10.3389/fonc.2020.599604 |
Ejemplares similares
-
Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nation‐wide multicenter study
por: Guo, Fengzhu, et al.
Publicado: (2021) -
A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
por: Wang, Jiayu, et al.
Publicado: (2023) -
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2023) -
Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis
por: Wang, Jiani, et al.
Publicado: (2022) -
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial
por: Xu, Binghe, et al.
Publicado: (2021)